Evidence map›Paper›PMID 22701756›Full record

ArticleOxidative medicine and cellular longevity2012

Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats.

José Luis Miguel-Carrasco, Ana Baltanás, Carolina Cebrián, María U Moreno, Begoña López, Nerea Hermida, Arantxa González, Javier Dotor, Francisco Borrás-Cuesta, Javier Díez and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. TRPC3 Channels in Cardiac Fibrosis.Frontiers in cardiovascular medicine · 2017
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

José Luis Miguel-CarrascoDivision of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.
Ana Baltanás
Carolina Cebrián
María U Moreno
Begoña López
Nerea Hermida
Arantxa González
Javier Dotor
Francisco Borrás-Cuesta
Javier Díez
Ana Fortuño
Guillermo Zalba
Universidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NADPH oxidases constitute a major source of superoxide anion (·O(2)(-)) in hypertension. Several studies suggest an important role of NADPH oxidases in different effects mediated by TGF-β 1. In this study we show that chronic administration of P144, a peptide synthesized from type III TGF-β 1 receptor, significantly reduced the cardiac NADPH oxidase expression and activity as well as in the nitrotyrosine levels observed in control spontaneously hypertensive rats (V-SHR) to levels similar to control normotensive Wistar Kyoto rats. In addition, P144 was also able to reduce the significant increases in the expression of collagen type I protein and mRNA observed in hearts from V-SHR. In addition, positive correlations between collagen expression, NADPH oxidase activity, and nitrotyrosine levels were found in all animals. Finally, TGF-β 1-stimulated Rat-2 exhibited significant increases in NADPH oxidase activity that was inhibited in the presence of P144. It could be concluded that the blockade of TGF-β 1 with P144 inhibited cardiac NADPH oxidase in SHR, thus adding new data to elucidate the involvement of this enzyme in the profibrotic actions of TGF-β 1.

Indexed as

Signal TransductionAnimalsBlood PressureCell LineCollagen Type IFibroblastsHeartHypertensionMaleMembrane GlycoproteinsMyocardiumNADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesPeptide FragmentsRats3-nitrotyrosineCollagen Type ICybb protein, ratMembrane GlycoproteinsNADPH Oxidase 2NADPH Oxidase 4NADPH OxidasesNox4 protein, ratPeptide FragmentsReceptors, Transforming Growth Factor betaTGF-beta1 type III receptor (730-743), humanTransforming Growth Factor beta1Tyrosine

Identifiers

PMID22701756
PMCPMC3372069
OpenAlexW2045437256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.